BRCA1 Mutation Clinical Trials

15 recruiting

BRCA1 Mutation Trials at a Glance

15 actively recruiting trials for brca1 mutation are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in New York, Boston, and Milan. Lead sponsors running brca1 mutation studies include Acerand Therapeutics (Shanghai) Limited, Associazione Italiana per lo Studio del Pancreas, and 858 Therapeutics, Inc..

Browse brca1 mutation trials by phase

Treatments under study

About BRCA1 Mutation Clinical Trials

Looking for clinical trials for BRCA1 Mutation? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new BRCA1 Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about BRCA1 Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Not Applicable

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

BRCA1 MutationBRCA2 Mutation
Duke University50 enrolled2 locationsNCT06972719
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Metastatic Solid TumorBRCA1 MutationBRCA2 Mutation+2 more
University of California, San Francisco24 enrolled1 locationNCT05694715
Recruiting
Phase 1

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA MutationBRCA1 MutationBRCA2 Mutation+3 more
Pamela Munster18 enrolled1 locationNCT06177171
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticPancreatic CancerHER2-negative Breast Cancer+9 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting
Phase 2

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD32 enrolled6 locationsNCT05498272
Recruiting
Phase 1Phase 2

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Breast CancerOvarian CancerProstate Cancer+3 more
Acerand Therapeutics (Shanghai) Limited298 enrolled14 locationsNCT06380660
Recruiting

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Breast CancerOvarian CancerLung Cancer+15 more
University Health Network, Toronto2,500 enrolled1 locationNCT03702309
Recruiting
Phase 2

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Advanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation+1 more
GBG Forschungs GmbH176 enrolled36 locationsNCT06201234
Recruiting

BRCA Mutation Carriers' Platform a Multicenter Study

BRCA1 MutationBRCA2 Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS10,000 enrolled40 locationsNCT07253051
Recruiting
Not Applicable

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

BRCA1 MutationBRCA2 MutationPOLD1 Gene Mutation+19 more
Memorial Sloan Kettering Cancer Center1,000 enrolled8 locationsNCT05420064
Recruiting
Not Applicable

FaCT Trial (Facilitated Cascade Testing Trial)

BRCA1 MutationBRCA2 Mutation
Weill Medical College of Cornell University820 enrolled3 locationsNCT04613440
Recruiting
Phase 1

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Breast CancerHER2-negative Breast CancerBRCA1 Mutation+2 more
Dana-Farber Cancer Institute20 enrolled3 locationsNCT06488378
Recruiting

Prostate Cancer Genetic Risk Evaluation and Screening Study

Prostate CancerBRCA1 MutationBRCA2 Mutation+5 more
Massachusetts General Hospital400 enrolled1 locationNCT05129605
Recruiting

Registry of Subjects at Risk of Pancreatic Cancer

BRCA1 MutationBRCA2 MutationLynch Syndrome+4 more
Associazione Italiana per lo Studio del Pancreas1,000 enrolled4 locationsNCT04095195